#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Remission of steroid-resistant Still’s disease treated with anakinra, evidenced by FDG-PET/CT examination: case report


Authors: Zdeněk Adam 1;  Jana Skřičková 2;  Milan Krtička 3;  Zdeněk Řehák 4,5;  Renata Koukalová 4;  Andrea Šprláková 6;  Marta Krejčí 1;  Luděk Pour 1;  Zdenka Adamová 7;  Eva Pourová 8;  Zdeněk Král 1
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice 1;  Klinika nemocí plicních a TBC LF MU a FN Brno, pracoviště Bohunice 2;  Klinika úrazové chirurgie LF MU a FN Brno, pracoviště Bohunice 3;  Oddělení nukleární medicíny MOÚ, Brno 4;  Regionální centrum molekulární onkologie (RECAMO) MOÚ, Brno 5;  Klinika radiologie a nukleární medicíny LF MU a FN Brno, pracoviště Bohunice 6;  Ordinace pro děti a dorost, Obilní trh, Brno 7;  Ordinace praktického lékaře pro dospělé, Pustiměř u Vyškova 8
Published in: Vnitř Lék 2017; 63(12): 987-997
Category: Case Reports

Overview

After elimination of infectious causes, neoplastic causes and the systemic autoimmune disease of connective tissue, a patient with high fevers over 39 °C was diagnosed with Still’s disease. High doses of prednisone led to resolution of symptoms, however after reducing the doses of prednisone to 15 mg, high fevers over 39 °C returned, as well as joint pains. The high doses of prednisone led to decompensation of diabetes mellitus even with 4 daily insulin dosages. Therefore it was proceeded to regular subcutaneous administration of anakinra once a day. Anakinra enabled the reduction of prednisone to as much as the currently administered 2.5 mg a day, but it has not so far allowed for removing glucocorticoids from the treatment completely. Activity of the disease is shown by the findings within the FDG-PET/CT examination. At the time of maximum activity of the disease there was distinct lymphadenopathy with pathological accumulation of FDG visible as well as increased accumulation of FDG in the hematopoietic bone marrow. As the disease activity decreased, the size of nodules regressed and FDG accumulation in both the lymphatic nodes and bone marrow declined. FDG-PET/CT is a suitable method for monitoring the activity of Still’s disease.

Key words:
anakinra – Adult-onset Still’s disease


Sources

1. Schneider T, Loddenkemper C, Rudwaleit M et al. Horečka nejasného původu v 21. století. Část 2: Neinfekční onemocnění. Medicína po promoci 2006; 7(3): 50–54.

2. Lachmann HJ. Autoinflammatory syndromes as causes of fever of unknown origin. Clin Med (Lond) 2015; 15(3): 295–298. Dostupné z DOI: <http://dx.doi.org/10.7861/clinmedicine.15–3-295>.

3. Król P, Doležalová P. Horečka jako hlavní projev nemoci. Pediatrie pro praxi 2011; 12(2): 111–114.

4. Doležalová P, Król P. Recidivující horečky u dětí. Vox pediatrie 2010; 10(3): 16–20.

5. Tomíčková D. Horečka neznámého původu. Lékařské listy 2009; 58(8): 9–11.

6. Křivanová A, Adam Z, Mayer J et al. Teplota nejasné etiologie: příčiny a diagnostický postup. Vnitř Lék 2007; 53(2): 169–178.

7. Solav SV. FDG PET/CT in evaluation of pyrexia of unknown origin. Clin Nucl Med 2011; 36(8): e81-e86. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0b013e31821c99b2>.

8. Kaya A, Ergul N, Kaya SY et al. The management and the diagnosis of fever of unknown origin. Expert Rev Anti Infect Ther 2013; 11(8): 805–815. Dostupné z DOI: <http://dx.doi.org/10.1586/14787210.2013.814436>.

9. Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still‘s disease. J Rheumatol 1992; 19(3): 424–430.

10. Fautrel B, Zing E, Golmard JL et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine 2002; 81(3): 194–200.

11. Bywaters EG. Still‘s disease in the adult. Annals Rheumatic Diseases 1971; 30(2): 121–133.

12. Owlia M, Mehrpoor G. Adult onset still’s disease: a review. Indian J Med Sci 2009; 63(5): 207–221. Dostupné z DOI: <http://dx.doi.org/10.4103/0019–5359.53169>.

13. Cagatay Y, Gul A, Cagatay A et al. Adult-onset still‘s disease. Int J Clin Pract 2009; 63(7): 1050–1055.

14. Komiya A, Matsui T, Nogi S et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still‘s disease. Scand J Rheumatol 2012; 41(2): 156–158. Dostupné z DOI: <http://dx.doi.org/10.3109/03009742.2011.644325>.

15. Chen DY, Lan JL, Lin FJ et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still‘s disease. J Rheumatol 2004; 31(11): 2189–2198.

16. Arlet JB, Boutin-Le D, Thi Huong J et al. Current concepts on the pathogenesis of adult-onset Still‘s disease. Rev Med Interne 2005; 26(7): 549–556.

17. Guilpain P, Le Quellec A. About the complexity of adult onset Still‘s disease…and advances still required for its management. BMC Med 2017; 15(1): 5. Dostupné z DOI: <http://dx.doi.org/10.1186/s12916–016–0769–1>.

18. Girard C, Rech J, Brown M et al. Elevated serum levels of free interleukin-18 in adult-onset Still‘s disease. Rheumatology (Oxford) 2016; 55(12): 2237–2247.

19. Ruscitti P, Cipriani P, Ciccia F et al. H-ferritin and CD68(+)/H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still‘s disease patients and correlate with the multi-visceral involvement of the disease. Clin Exp Immunol 2016; 186(1): 30–38. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12826>.

20. Inoue N, Shimizu M, Tsunoda S et al. Cytokine profile in adult-onset Still‘s disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol 2016; 169: 8–13. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2016.05.010>.

21. Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol 2015; 159(1): 72–83. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2015.04.018>.

22. Colafrancesco S, Priori R, Valesini G Presentation and diagnosis of adult-onset Still‘s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol 2015; 11(6): 749–761. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2015.1037287>.

23. Skácelová M, Horák P. Stillova choroba dospělých. Postgraduální medicína 2015; 17(4): 391–394.

24. Jarošová K. Kazuistika dospělé pacientky se Stillovou chorobou léčené anakinrou. Farmakoterapie 2012; 8(Suppl 1): 10–11.

25. Skácelová M, Horák P. Stillova nemoc dospělých – kazuistika. Česká revmatologie 2012; 20(4): 198–202.

26. Houzarová A. Stillova nemoc. Referátový výběr z revmatologie. 2007; 47(3): 1214–1220.

27. Jarošová K. Stillova choroba v dospělosti. Česká revmatologie 2006; 14(4): 159–163.

28. Lachmann HJ. Autoinflammatory syndromes as causes of fever of unknown origin. Clin Med (Lond) 2015; 15(3): 295–298. Dostupné z DOI: <http://dx.doi.org/10.7861/clinmedicine.15–3-295>.

29. Cagatay Y, Gul A, Cagatay A et al. Adult-onset still‘s disease. Intern J Clin Practice 2009; 63(7): 1050–1055.

30. Mert A, Ozaras R, Tabak F et al. Fever of unknown origin: a review of 20 patients with adult-onset Still‘s disease. Clin Rheumatol 2003; 22(2): 89–93.

31. Chen DY, Lan HC, Hsieh TY et al. Crico-thyroid perichondritis leading to sore throat in patients with active adult-onset Still‘s disease. Ann Rheum Dis 2007; 66(9): 1264–1266.

32. Cetkovská P, Benáková N. Autoinflamatorní syndromy s kožními projevy. Česko-slov Derm 2015; 90(4): 144–155.

33. Mehrpoor G, Owlia M, Soleimani H et al. Adult-onset Still‘s disease: a report of 28 cases and review of the literature. Modern Rheumatol 2008; 18(5): 480–485. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–008–0104–6>.

34. Kojima M, Nakamura S, Miyawaki S et al. Lymph node lesion in adult-onset still‘s disease resembling peripheral T-cell lymphoma: a report of three cases. Intern J Surgical Pathology 2002; 10(3): 197–202.

35. Dong MJ, Wang CQ, Zhao K et al. 18F-FDG PET/CT in patients with adult-onset Still‘s disease. Clin Rheumatol 2015; 34(12): 2047–2056. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–015–2901–6>.

36. Roy SG, Karunanithi S, Dhull VS et al. ¹⁸F-FDG PET/CT aids the diagnosis of adult onset Still‘s disease in a patient with fever of unknown origin. Rev Esp Med Nucl Imagen Mol 2014; 33(6): 392–393. Dostupné z DOI: <http://dx.doi.org/10.1016/j.remn.2014.03.001>.

37. Gerfaud-Valentin M, Maucort-Boulch D, Hot A et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014; 93(2): 91–99. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000000021>.

38. Yamashita H, Kubota K, Takahashi Y et al. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still‘s disease: a seven-case series and review of the literature. Mod Rheumatol 2014; 24(4): 645–650. Dostupné z DOI: <http://dx.doi.org/10.3109/14397595.2013.850998>.

39. Cai L, Chen Y, Huang Z. Elevated FDG activity in lymph nodes as well as the spleen and liver in a patient with adult-onset still disease. Clin Nucl Med 2012; 37(10): 1009–1010. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0b013e31826386d2>.

40. de Graaff LC, ten Broek MR, Schweitzer DH. Is Still‘s disease still one disease? A case of Adult-onset Still‘s disease showing accumulation in the carotids and the large vessels of the legs on positron emission tomography: CT images. Rheumatol Int 2012; 32((8): 2487–2490. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–011–1991-y>.

41. Choe JY, Chung DS, Park SH et al. Clinical significance of ¹⁸F-fluoro-dexoxyglucose positron emission tomography in patients with adult-onset Still‘s disease: report of two cases and review of literatures. Rheumatol Int 2010; 30(12): 1673–1676. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–009–1137–7>.

42. Funauchi M, Ikoma S, Kishimoto K et al. A case of adult onset Still‘s disease showing marked accumulation in the liver and spleen, on positron emission tomography-CT images. Rheumatol Int 2008; 28(10): 1061–1064. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–008–0562–3>.

43. Chvojka J, Kroužecký A, Raděj J et al. 24letý muž s horečkami, multiorgánovou dysfunkcí a rychle progredujícím ARDS. Vnitř Lék 2009; 55(10): 991–994.

44. Tomš J, Soukup T, Polák J et al. Multiorgánové selhání a syndrom aktivovaných makrofágů u Stillovy nemoci v dospělosti. Česká revmatologie 2012; 20(3): 115–119 (e133-e137).

45. Kočan L, Vašková J, Vaško L et al. Ťažký priebeh Stillovej choroby s multiorgánovým zlyhávaním a závažnou pečeňovou dysfunkciou. Anest Intenziv Med 2011; 22(6): 337–342.

46. Tristano EG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008; 14(3): 27–36.

47. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003; 15(5): 587–590.

48. Kelly J, Chowienczyk M, Gibson T. Sore throat and hyperferritinaemia. J R Soc Med 2001; 94(8): 400–401.

49. Meijvis SCA, Endeman H, Geers AB et al. Extremely high serum ferritin levels as diagnosis tool in adult-onset Still‘s disease. Neth J Med 2007; 65(6): 212–214.

50. Fardet, L, Coppo P, Kettaneh A et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 2008; 58(5): 1521–1527. Dostupné z DOI: <http://dx.doi.org/10.1002/art.23415>.

51. Efthimiou F, Paik FK, Bielory L. Diagnosis and management of adult onset Still‘s disease. Ann Rheumatic Dis 2006; 65(5): 564–572.

52. Padeh H. Periodic fever syndromes. Pediatr Clin North Am 2005; 52(2): 577–609.

53. Šedivá A, Maňásek V, Gřegořová A et al. Familiární středomořská horečka v České republikace. Vnitř Lék 2014; 60(1): 25–29.

54. Šedivá A, Horváth R, Maňásek V et al. Cluster of patients with Familial Mediterranean fever and heterozygous carriers of mutations in MEFV gene in the Czech Republic. Clin Genet 2014; 86(6): 564–569. Dostupné z DOI: <http://dx.doi.org/10.1111/cge.12323>.

55. Toplak N, Dolezalovà P, Constantin T et al. [Eastern/Central European autoinflammatory collaborating group for the Paediatric Rheumatology International Trials Organization (PRINTO) and Eurofever Project]. Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J 2010; 8: 29. Dostupné z DOI: <http://dx.doi.org/10.1186/1546–0096–8-29>.

56. Vannucci G, Cantarini L, Giani T et al. Glucocorticoids in the management of systemic juvenile idiopathic arthritis. Paediatr Drugs 2013; 15(5): 343–349. Dostupné z DOI: <http://dx.doi.org/10.1007/s40272–013–0038–0>.

57. Castañeda S, Blanco R, González-Gay MA. Adult-onset Still‘s disease: Advances in the treatment. Best Pract Res Clin Rheumatol 2016; 30(2): 222–238. Dostupné z DOI: <http://dx.doi.org/10.1016/j.berh.2016.08.003>.

58. Okamoto O, Oishi M, Fujiwara S. Steroid-resistant adult-onset Still‘s disease which showed a quick response to methotrexate. J Dermatol 2008; 35(2): 106–110. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1346–8138.2008.00424.x>.

59. Jung JH, Jun JB, Yoo DH et al. High toxicity of sulfasalazine in adult-onset Still‘s disease. Clin Exp Rheumatol 2000; 18(2): 245–248.

60. Šedivá A, Slíva J, Doležalová P et al. Anakinra. Farmakoterapie 2011; 7(6): 621–629.

61. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still‘s disease successfully treated with Anakinra. Ann Rheum Dis 2005; 64(4): 647–648.

62. Kötter I, Wacker A, Koch S et al. Anakinra in patients with treatment-resistant adult-onset still‘s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007; 37(3): 189–197.

63. Jamilloux J, Gerfaud-Valentin M, Henry T et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag 2014; 11: 33–43. Dostupné z DOI: <http://dx.doi.org/10.2147/TCRM.S64951>.

64. Parisi F, Paglionico A, Varriano V et al. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra. Medicine (Baltimore) 2017; 96(24): e6656. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000006656>.

65. Proft F, Fleck M, Fiehn C et al. Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases: Experiences from a German registry (GRAID2). Z Rheumatol 2017. Dostupné z DOI: <http://dx.doi.org/10.1007/s00393–017–0329-x>.

66. Castañeda S, Blanco R, González-Gay MA. Adult-onset Still‘s disease: Advances in the treatment. Best Pract Res Clin Rheumatol 2016; 30(2): 222–238. Dostupné z DOI: <http://dx.doi.org/10.1016/j.berh.2016.08.003>.

67. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L et al. Efficacy of Anakinra in Refractory Adult-Onset Still‘s Disease: Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore) 2015; 94(39): e1554. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000001554>

68. Waghmare S, Valecka B, Cairns AP. A severe case of adult onset Still disease with myoperikarditis resistant do treatment with tocilizumab but responsive to anakinra. Ulster Med J 2015; 84(2): 130–132.

69. Cavalli G, Franchini S, Aiello P et al. Efficacy and safety of biological agents in adult-onset Still‘s disease. Scand J Rheumatol 2015; 44(4): 309–314. Dostupné z DOI: <http://dx.doi.org/10.3109/03009742.2014.992949>.

70. Hong D, Yang Z, Han S et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 2014; 8: 2345–2357. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.S73428>.

71. Yilmaz S, Cinar M, Simsek I et al. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still‘s Disease. Mod Rheumatol 2014; 24(6): 1030–1031. Dostupné z DOI: <http://dx.doi.org/10.3109/14397595.2013.854437>.

72. Al-Homood IA. Biologic treatments for adult-onset Still‘s disease. Rheumatology (Oxford) 2014; 53(1): 32–38. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket250>.

73. Giampietro C, Ridene M, Lequerre T et al. Anakinra in adult-onset Still‘s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 2013; 65(5): 822–8226. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21901>.

74. Nordström D, Knight A, Luukkainen R et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still‘s disease. An open, randomized, multicenter study. J Rheumatol 2012; 39(10): 2008–2011. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.111549>.

75. Lahiri M, Teng GG. A case of refractory adult-onset Still‘s disease treated with anakinra. Int J Rheum Dis 2010; 13(3): e36-e41. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1756–185X.2010.01474.x>.

76. Moulis G, Sailler L, Astudillo L et al. May anakinra be used earlier in adult onset Still disease? Clin Rheumatol 2010; 29(10): 1199–1200. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–010–1459–6>.

77. Ilowite NT, Prather K, Lokhnygina Y et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66(9): 2570–2579. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38699>.

78. Mitha E, Schumacher HR, Fouche L et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013; 52(7): 1285–1292. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket114>.

79. Lovell DJ, Giannini EH, Reiff AO et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013; 65(9): 2486–2496. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38042>.

80. Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still‘s disease. Ann Rheum Dis 2012; 71(12): 2056–2057. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2012–201409>.

81. Krause K, Weller K, Stefaniak R et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67(7): 943–950. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1398–9995.2012.02843.x>.

82. Schumacher HR Jr, Evans RR, Saag KG et al. Rilonacept (interleukin-1 trap) for revention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012; 64(10): 1462–1470. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21690>.

83. Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol 2011; 71(5): 639–641. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2125.2011.03958.x>.

84. Kone-Paut I, Quartier P, Fain O et al. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care Res (Hoboken) 2017; 69(6): 903–911. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.23083>.

85. Barsotti S, Neri R, Iacopetti V et al. Successful treatment of refractory adult-onset Still disease with canakinumab: a case report. J Clin Rheumatol 2014; 20(2): 121. Dostupné z DOI: <http://dx.doi.org/10.1097/RHU.0000000000000082>.

86. Lo Gullo A, Caruso A, Pipitone N et al. Canakinumab in a case of adult onset still‘s disease: efficacy only on systemic manifestations. Joint Bone Spine 2014; 81(4): 376–377. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2013.12.011>.

87. Perez-Ruiz F, Chinchilla SP, Herrero-Beites AM. Canakinumab for gout: a specific, patient-profiled indication. Expert Rev Clin Immunol 2014; 10(3): 339–347. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2014.880653>.

88. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis in the biologic age. Rheum Dis Clin North Am 2013; 39(4): 751–766. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rdc.2013.05.004>.

89. Banse C, Vittecoq O, Benhamou Y et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still‘s disease. Joint Bone Spine 2013; 80(6): 653–655. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2013.04.011>.

90. Vandemergel X, Vandergheynst F. Efficacy of low-dose tocilizumab on relapsing adult-onset still‘s disease. Acta medica (Hradec Králové) 2016; 59(1): 22–25. Dostupné z DOI: <http://dx.doi.org/10.14712/18059694.2016.51>.

91. Cipriani P, Ruscitti P, Carubbi F et al. Tocilizumab for the treatment of adult-onset Still‘s disease: results from a case series. Clin Rheumatol 2014; 33(1): 49–55. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–013–2381–5>.

92. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still‘s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014; 66(6): 1659–1665. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38398>.

93. Nishina N, Kaneko Y, Kameda H et al. The effect of tocilizumab on preventing relapses in adult-onset Still‘s disease: A retrospective, single-center study. Mod Rheumatol 2015; 25(3): 401–404. Dostupné z DOI: <http://dx.doi.org/10.3109/14397595.2014.973659>.

94. Gerfaud-Valentin M, Jamilloux Y, Iwaz J et al. Adult-onset Still‘s disease. Autoimmun Rev 2014; 13(7): 708–722. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2014.01.058>.

95. Suematsu R, Ohta A, Matsuura E et al. Therapeutic response of patients with adult Still‘s disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2012; 22(5): 712–719. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–011–0569–6>.

96. Maeshima K, Ishii K, Iwakura M et al. Adult-onset Still‘s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Mod Rheumatol 2012; 22(): 137–141. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–011–0477–9>.

97. Babacan T, Onat AM, Pehlivan Y et al. Successful treatment of refractory adult Still‘s disease and membranous glomerulonephritis with infliximab. Clin Rheumatol 2010; 29(4): 423–426. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–009–1331–8>.

98. Thonhofer R, Soleiman A, Kriessmayr M et al. Decrease of proteinuria in a patient with adult-onset Still‘s disease and glomerulonephritis after anti-TNF alpha therapy. Scand J Rheumatol 2006; 35(6): 485–488.

99. Huffstutter JE, Sienknecht CW. Treatment of resistant adult still disease with infliximab: a report of 2 cases. J Clin Rheumatol 2004; 10(4): 218–221.

100. Dilhuydy MS, Vatan R, Etienne G et al. Prolonged efficacy of infliximab for refractory adult-onset Still‘s disease. Clin Exp Rheumatol 2005; 23(1): 121–122.

101. Fautrel B, Sibilia J, Mariette X et al. Tumour necrosis factor alpha blocking agents in refractory adult Still‘s disease: an observational study of 20 cases. Ann Rheum Dis 2005; 64(2): 262–266.

102. Ito T, Ozaki Y, Shimamoto K et al. Successful treatment with plasma exchange in adult-onset Still‘s disease with hyper-IL-18-naemia and hyperallergic state. Modern Rheumatol 2008; 18(4): 407–410. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–008–0065–9>.

103. Mahmud H, Hughes GR. Intravenous immunoglobulin in the treatment of refractory adult Still‘s disease. J Rheumatol 1999; 26(9): 2067–2068.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#